CDPath: Cooperative Driver Pathways Discovery Using Integer Linear Programming and Markov Clustering

Discovering driver pathways is an essential task to understand the pathogenesis of cancer and to design precise treatments for cancer patients. Increasing evidences have been indicating that multiple pathways often function cooperatively in carcinogenesis. In this study, we propose an approach called CDPath to discover cooperative driver pathways. CDPath firstly uses Integer Linear Programming to explore driver core modules from mutation profiles by enforcing co-occurrence and functional interaction relations between modules, and by maximizing the mutual exclusivity and coverage within modules. Next, to enforce cooperation of pathways and help the follow-up exact cooperative driver pathways discovery, it performs Markov clustering on pathway-pathway interaction network to cluster pathways. After that, it identifies pathways in different modules but in the same clusters as cooperative driver pathways. We apply CDPath on two TCGA datasets: breast cancer (BRCA) and endometrial cancer (UCEC). The results show that CDPath can identify known (i.e., TP53) and potential driver genes (i.e., SPTBN2). In addition, the identified cooperative driver pathways are related with the target cancer, and they are involved with carcinogenesis and several key biological processes. CDPath can uncover more potential biological associations between pathways (over 100%) and more cooperative driver pathways (over 200%) than competitive approaches.

[1]  Srinivasan Parthasarathy,et al.  Identifying functional modules in interaction networks through overlapping Markov clustering , 2012, Bioinform..

[2]  J. Dai,et al.  IGF-1 from adipose-derived mesenchymal stem cells promotes radioresistance of breast cancer cells. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[3]  Simo V. Zhang,et al.  A map of human cancer signaling , 2007, Molecular systems biology.

[4]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[5]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[6]  klaguia.  International Network of Cancer Genome Projects , 2010 .

[7]  H. Zhang,et al.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. , 2008, Breast cancer research and treatment.

[8]  Junhua Zhang,et al.  The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms , 2016, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[9]  Q. Zhang,et al.  HOTTIP regulates progression of endometrial cancer via activating PI3K/AKT pathway. , 2018, European review for medical and pharmacological sciences.

[10]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[11]  K. Shilo,et al.  Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti‐tumor mechanisms of Cannabidiol in breast cancer , 2015, Molecular oncology.

[12]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[13]  A. Giuliano,et al.  Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. , 2014, JAMA surgery.

[14]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[15]  Alfonso Valencia,et al.  Chapter 14: Cancer Genome Analysis , 2012, PLoS Comput. Biol..

[16]  Shoshana J. Wodak,et al.  Markov clustering versus affinity propagation for the partitioning of protein interaction graphs , 2009, BMC Bioinformatics.

[17]  Shi-Hua Zhang,et al.  Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data , 2013, BMC Systems Biology.

[18]  Chenguang Wang,et al.  Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma. , 2013, Molecular bioSystems.

[19]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[20]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[21]  Eli Upfal,et al.  De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.

[22]  M. Sherman,et al.  p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. , 1995, Human pathology.

[23]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[24]  Yajie Yin,et al.  Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways. , 2018, American journal of translational research.

[25]  Teresa M. Przytycka,et al.  WeSME: uncovering mutual exclusivity of cancer drivers and beyond , 2016, Bioinform..

[26]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[27]  S. Batra,et al.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells , 2010, Oncogene.

[28]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[29]  R. Fodde,et al.  Alterations in Wnt–β‐catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression , 2013, The Journal of pathology.

[30]  S. vanDongen.  Graph Clustering by Flow Simulation , 2000 .

[31]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[32]  Roded Sharan,et al.  Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..

[33]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[34]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[35]  C. Yeang,et al.  Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[37]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010 .

[38]  Yunyan Gu,et al.  Analysis of pathway mutation profiles highlights collaboration between cancer‐associated superpathways , 2011, Human mutation.

[39]  H. Hondermarck,et al.  Proteome changes induced by overexpression of the p75 neurotrophin receptor (p75NTR) in breast cancer cells. , 2011, The International journal of developmental biology.

[40]  Jacques van Helden,et al.  Evaluation of clustering algorithms for protein-protein interaction networks , 2006, BMC Bioinformatics.

[41]  Shihua Zhang,et al.  Discovery of cancer common and specific driver gene sets , 2016, Nucleic acids research.

[42]  Shi-Hua Zhang,et al.  Efficient methods for identifying mutated driver pathways in cancer , 2012, Bioinform..

[43]  Roded Sharan,et al.  BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions , 2017, PLoS Comput. Biol..

[44]  Shi-Hua Zhang,et al.  Discovery of co-occurring driver pathways in cancer , 2014, BMC Bioinformatics.

[45]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[46]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.